Esomeprazole
Identification
- Name
- Esomeprazole
- Accession Number
- DB00736 (APRD00363)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]
- Structure
- Synonyms
- (−)-omeprazole
- (S)-(−)-omeprazole
- (S)-omeprazole
- Esomeprazol
- Ésoméprazole
- Esomeprazolum
- Omeprazole S-form
- Perprazole
- External IDs
- A02BC05 / H 199/18
- Product Ingredients
Ingredient UNII CAS InChI Key Esomeprazole magnesium 925R0D7W1O 161973-10-0 KWORUUGOSLYAGD-YPPDDXJESA-N Esomeprazole magnesium dihydrate 36H71644EQ 217087-10-0 DBOUSUONOXEWHU-VCKZSRROSA-N Esomeprazole magnesium trihydrate R6DXU4WAY9 217087-09-7 VEVZQDGATGBLIC-UHFFFAOYSA-N Esomeprazole sodium L2C9GWQ43H 161796-78-7 RYXPMWYHEBGTRV-JIDHJSLPSA-N Esomeprazole strontium SCC2RK476A 914613-86-8 FEVPVZSYBDUVGY-YPPDDXJESA-N Esomeprazole strontium hydrate C5N25H3803 934714-36-0 NCGHIAKEJNQSMS-QLGOZJDFSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Esomeprazole Tablet, delayed release 20 mg Oral Teva 2015-11-09 Not applicable Canada Act Esomeprazole Tablet, delayed release 40 mg Oral Teva 2015-11-09 Not applicable Canada Esomeprazole Tablet, delayed release 40 mg Oral Sanis Health Inc 2014-09-22 Not applicable Canada Esomeprazole Tablet, delayed release 20 mg Oral Ranbaxy Inc. Not applicable Not applicable Canada Esomeprazole Tablet, delayed release 20 mg Oral Ethypharm Not applicable Not applicable Canada Esomeprazole Tablet, delayed release 20 mg Oral Teva Not applicable Not applicable Canada Esomeprazole Tablet, delayed release 40 mg Oral Pro Doc Limitee 2012-11-22 Not applicable Canada Esomeprazole Tablet, delayed release 40 mg Oral Sivem Pharmaceuticals Ulc 2015-07-22 Not applicable Canada Esomeprazole Tablet, delayed release 20 mg Oral Sivem Pharmaceuticals Ulc 2015-07-22 Not applicable Canada Esomeprazole Tablet, delayed release 20 mg Oral Pro Doc Limitee 2013-06-06 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Anodyne Ile Kit Fortus Pharma, Llc 2017-10-16 Not applicable US Apo-esomeprazole Tablet, delayed release 40 mg Oral Apotex Corporation 2011-03-07 Not applicable Canada Apo-esomeprazole Tablet, delayed release 20 mg Oral Apotex Corporation 2012-03-02 Not applicable Canada Esomeprazole Magnesium Capsule, delayed release 40 mg/1 Oral North Star Rx Llc 2017-08-14 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Amerincan Health Packaging 2017-03-15 Not applicable US Esomeprazole Magnesium Capsule, delayed release 40 mg/1 Oral Torrent Pharmaceuticals Limited 2015-10-19 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Aurobindo Pharma 2016-04-21 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 1/1 Oral Nu Care Pharmaceuticals,inc. 2015-10-19 Not applicable US Esomeprazole Magnesium Capsule, delayed release 40 1/1 Oral Remedy Repack 2016-12-07 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Camber Pharmaceuticals 2015-09-21 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Basic Care Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral L. Perrigo Company 2018-01-09 Not applicable US Berkley and Jensen Heartburn Treatment Capsule, delayed release 20 mg/1 Oral BJWC 2017-09-25 Not applicable US Careone Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral American Sales Company 2017-09-26 Not applicable US DG Health Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Dolgencorp 2017-09-22 Not applicable US Equaline Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Supervalu 2017-09-25 Not applicable US Equate Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Walmart Stores 2017-10-05 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Family Dollar 2017-10-16 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Walmart Stores 2017-10-16 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Kroger 2017-09-22 Not applicable US Esomeprazole Magnesium Capsule, delayed release 20 mg/1 Oral Sam's West, Inc 2017-10-16 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Mylan-naproxen/esomeprazole Mr Esomeprazole (20 mg) + Naproxen (375 mg) Tablet, delayed release Oral Mylan Pharmaceuticals 2017-02-27 Not applicable Canada Mylan-naproxen/esomeprazole Mr Esomeprazole (20 mg) + Naproxen (500 mg) Tablet, delayed release Oral Mylan Pharmaceuticals 2017-02-10 Not applicable Canada Vimovo Esomeprazole (20 mg) + Naproxen (375 mg) Tablet, delayed release Oral Astra Zeneca 2011-02-04 Not applicable Canada Vimovo Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1) Tablet, delayed release Oral Stat Rx USA 2011-07-01 2018-02-08 US Vimovo Esomeprazole magnesium (20 mg/1) + Naproxen (500 mg/1) Tablet, delayed release Oral Astra Zeneca Lp 2010-07-06 2017-03-31 US Vimovo Esomeprazole magnesium (20 mg/1) + Naproxen (500 mg/1) Tablet, delayed release Oral Horizon Pharma, Inc. 2014-01-01 Not applicable US Vimovo Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1) Tablet, delayed release Oral Astra Zeneca Lp 2010-07-06 2017-03-31 US Vimovo Esomeprazole (20 mg) + Naproxen (500 mg) Tablet, delayed release Oral Astra Zeneca 2011-02-04 Not applicable Canada Vimovo Esomeprazole magnesium (20 mg/1) + Naproxen (375 mg/1) Tablet, delayed release Oral Horizon Pharma, Inc. 2014-01-01 Not applicable US - International/Other Brands
- Alenia (Delta) / Awa-Block (Usawa) / Axagon (Simesa) / Cor (Prater) / Cronopep (Biotoscana) / Emanera (Krka) / Emep (Aristopharma) / Emozul (HYGIA) / ES-OD (Piramal Healthcare) / Esmep (HYGIA) / Eso (Asiatic Lab) / Esofag (Micro Labs) / Esogastrosedol (Nova Argentia) / Esolok (Ibn Sina) / Esomarfan (Marfan) / Esomenta (RAK) / Esomep (ACI) / Esomeprazol Genfar (Genfar S.A) / Esopral (Maquifarma) / Esorest (Centaur) / Inexium paranova / Lucen (Malesci) / Nexiam (AstraZeneca)
- Categories
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Benzimidazoles
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (moderate)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Enzyme Inhibitors
- Gastrointestinal Agents
- Omeprazole
- Proton Pump Inhibitors
- Proton-pump Inhibitors
- Pyridines
- Sulfoxides
- Sulfur Compounds
- UNII
- N3PA6559FT
- CAS number
- 119141-88-7
- Weight
- Average: 345.416
Monoisotopic: 345.114712179 - Chemical Formula
- C17H19N3O3S
- InChI Key
- SUBDBMMJDZJVOS-DEOSSOPVSA-N
- InChI
- InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1
- IUPAC Name
- 5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
- SMILES
- COC1=CC2=C(NC(=N2)[[email protected]@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Pharmacology
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Structured Indications
- Pharmacodynamics
Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
- Mechanism of action
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
Target Actions Organism APotassium-transporting ATPase alpha chain 1 inhibitorHuman - Absorption
90%
- Volume of distribution
- 16 L [healthy volunteers]
- Protein binding
97%
- Metabolism
Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome P450 system via CYP2C19 and CYP3A4. Metabolism produces inactive hydroxy and desmethyl metabolites, which have no effect on gastric acid secretion. Less than 1% of the parent drug is excreted in urine.
- Route of elimination
Approximately 80% of the administered dose of esomeprazole is excreted as metabolites in urine and the remaining 20% is excreted in feces.
- Half life
1-1.5 hours
- Clearance
- Not Available
- Toxicity
Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid heartbeat, sweating
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Esomeprazole Metabolism Pathway Drug metabolism Esomeprazole Action Pathway Drug action - Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2C19 CYP2C19*2 (A;A) A Allele, homozygote Effect Directly Studied Patients with this genotype have reduced metabolism of esomeprazole. Details Cytochrome P450 2C19 CYP2C19*3 (A;A) A Allele, homozygote Effect Directly Studied Patients with this genotype have reduced metabolism of esomeprazole. Details Cytochrome P450 2C19 CYP2C19*2A Not Available 681G>A Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*2B Not Available 681G>A Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*4 Not Available 1A>G Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*5 Not Available 1297C>T Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*6 Not Available 395G>A Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*7 Not Available 19294T>A Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*22 Not Available 557G>C / 991A>G Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*24 Not Available 99C>T / 991A>G … show all Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details Cytochrome P450 2C19 CYP2C19*35 Not Available 12662A>G Effect Inferred Poor metabolizer, lower dose requirement, improved drug efficacy Details
Interactions
- Drug Interactions
Drug Interaction Drug group Abiraterone The metabolism of Esomeprazole can be decreased when combined with Abiraterone. Approved Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Esomeprazole. Approved, Investigational Adinazolam The metabolism of Adinazolam can be decreased when combined with Esomeprazole. Approved Alendronic acid The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole. Approved Almotriptan The metabolism of Almotriptan can be decreased when combined with Esomeprazole. Approved, Investigational Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Esomeprazole. Approved, Investigational Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Esomeprazole. Approved, Withdrawn Amiodarone The metabolism of Esomeprazole can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Esomeprazole. Approved Amoxicillin The metabolism of Amoxicillin can be decreased when combined with Esomeprazole. Approved, Vet Approved Amphetamine Esomeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Illicit, Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Esomeprazole. Approved, Investigational Apalutamide The serum concentration of Esomeprazole can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The metabolism of Apixaban can be decreased when combined with Esomeprazole. Approved Aprepitant The serum concentration of Esomeprazole can be increased when it is combined with Aprepitant. Approved, Investigational Arformoterol The metabolism of Arformoterol can be decreased when combined with Esomeprazole. Approved, Investigational Armodafinil The metabolism of Esomeprazole can be decreased when combined with Armodafinil. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Esomeprazole. Approved Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Esomeprazole. Approved, Investigational, Withdrawn Atazanavir Esomeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Atomoxetine The metabolism of Esomeprazole can be decreased when combined with Atomoxetine. Approved Axitinib The metabolism of Axitinib can be decreased when combined with Esomeprazole. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Esomeprazole. Approved Benzatropine The metabolism of Benzatropine can be decreased when combined with Esomeprazole. Approved Boceprevir The metabolism of Esomeprazole can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Esomeprazole can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Esomeprazole can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Esomeprazole. Approved Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Esomeprazole. Approved, Investigational Bromazepam The metabolism of Bromazepam can be decreased when combined with Esomeprazole. Approved, Illicit, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Esomeprazole. Approved Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Esomeprazole. Approved, Investigational Cannabidiol The metabolism of Cannabidiol can be decreased when combined with Esomeprazole. Approved, Investigational Carbamazepine The metabolism of Esomeprazole can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Esomeprazole. Approved Carisoprodol The metabolism of Carisoprodol can be decreased when combined with Esomeprazole. Approved Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Esomeprazole. Approved, Investigational Ceritinib The serum concentration of Esomeprazole can be increased when it is combined with Ceritinib. Approved Chloramphenicol The metabolism of Esomeprazole can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Esomeprazole. Approved, Investigational Cholecalciferol The metabolism of Esomeprazole can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Esomeprazole. Approved, Investigational Cimetidine The metabolism of Esomeprazole can be decreased when combined with Cimetidine. Approved, Investigational Cisapride The metabolism of Cisapride can be decreased when combined with Esomeprazole. Approved, Investigational, Withdrawn Citalopram The serum concentration of Citalopram can be increased when it is combined with Esomeprazole. Approved Clarithromycin The metabolism of Esomeprazole can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Esomeprazole can be decreased when combined with Clemastine. Approved, Investigational Clobazam The metabolism of Clobazam can be decreased when combined with Esomeprazole. Approved, Illicit Clodronic Acid The therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Esomeprazole. Approved, Investigational, Vet Approved clomethiazole The metabolism of clomethiazole can be decreased when combined with Esomeprazole. Investigational Clomipramine The metabolism of Clomipramine can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Clopidogrel Esomeprazole may decrease the antiplatelet activities of Clopidogrel. Approved Clorindione The serum concentration of Clorindione can be increased when it is combined with Esomeprazole. Experimental Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Esomeprazole. Approved, Illicit Clotrimazole The metabolism of Esomeprazole can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Esomeprazole. Approved Cobicistat The metabolism of Esomeprazole can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Esomeprazole. Approved, Investigational Crizotinib The metabolism of Esomeprazole can be decreased when combined with Crizotinib. Approved Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Esomeprazole. Approved, Investigational Cyclosporine The metabolism of Esomeprazole can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cysteamine The therapeutic efficacy of Cysteamine can be decreased when used in combination with Esomeprazole. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy. Approved Dabrafenib The serum concentration of Dabrafenib can be decreased when it is combined with Esomeprazole. Approved, Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Esomeprazole. Approved, Investigational Darunavir The metabolism of Esomeprazole can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Dasatinib can be decreased when it is combined with Esomeprazole. Approved, Investigational Deferasirox The serum concentration of Esomeprazole can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Esomeprazole. Approved Desipramine The metabolism of Desipramine can be decreased when combined with Esomeprazole. Approved, Investigational Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Esomeprazole. Approved, Investigational Dexmethylphenidate Esomeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Investigational Dextroamphetamine Esomeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Illicit Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Esomeprazole. Approved Diazepam The metabolism of Diazepam can be decreased when combined with Esomeprazole. Approved, Illicit, Investigational, Vet Approved Diclofenac The metabolism of Diclofenac can be decreased when combined with Esomeprazole. Approved, Vet Approved Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Esomeprazole. Approved Dihydroergotamine The metabolism of Esomeprazole can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem The metabolism of Esomeprazole can be decreased when combined with Diltiazem. Approved, Investigational Diphenadione The serum concentration of Diphenadione can be increased when it is combined with Esomeprazole. Experimental Diphenhydramine The metabolism of Diphenhydramine can be decreased when combined with Esomeprazole. Approved, Investigational Dopamine The metabolism of Dopamine can be decreased when combined with Esomeprazole. Approved Doxazosin The metabolism of Doxazosin can be decreased when combined with Esomeprazole. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Esomeprazole. Approved, Investigational Doxycycline The metabolism of Esomeprazole can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The metabolism of Dronabinol can be decreased when combined with Esomeprazole. Approved, Illicit Dronedarone The metabolism of Esomeprazole can be decreased when combined with Dronedarone. Approved Efavirenz The metabolism of Esomeprazole can be decreased when combined with Efavirenz. Approved, Investigational Eletriptan The metabolism of Eletriptan can be decreased when combined with Esomeprazole. Approved, Investigational Enasidenib The metabolism of Enasidenib can be decreased when combined with Esomeprazole. Approved, Investigational Enfuvirtide The metabolism of Enfuvirtide can be decreased when combined with Esomeprazole. Approved, Investigational Enzalutamide The serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide. Approved Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Esomeprazole. Approved, Investigational Erythromycin The metabolism of Esomeprazole can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The metabolism of Escitalopram can be decreased when combined with Esomeprazole. Approved, Investigational Eslicarbazepine acetate The metabolism of Esomeprazole can be decreased when combined with Eslicarbazepine acetate. Approved Estradiol The metabolism of Estradiol can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Estradiol acetate The metabolism of Estradiol acetate can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Estradiol benzoate The metabolism of Estradiol benzoate can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Estradiol cypionate The metabolism of Estradiol cypionate can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Estradiol dienanthate The metabolism of Estradiol dienanthate can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Estradiol valerate The metabolism of Estradiol valerate can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Esomeprazole. Withdrawn Etidronic acid The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Esomeprazole. Approved Etizolam The metabolism of Etizolam can be decreased when combined with Esomeprazole. Approved Etravirine The metabolism of Etravirine can be decreased when combined with Esomeprazole. Approved Famotidine The metabolism of Famotidine can be decreased when combined with Esomeprazole. Approved Ferric Carboxymaltose Esomeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ferric pyrophosphate Esomeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Fluconazole The serum concentration of Esomeprazole can be increased when it is combined with Fluconazole. Approved, Investigational Fluindione The serum concentration of Fluindione can be increased when it is combined with Esomeprazole. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Esomeprazole. Approved, Illicit Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Esomeprazole. Approved, Vet Approved Flutamide The metabolism of Flutamide can be decreased when combined with Esomeprazole. Approved, Investigational Fluvoxamine The metabolism of Esomeprazole can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol The metabolism of Formoterol can be decreased when combined with Esomeprazole. Approved, Investigational Fosamprenavir The metabolism of Esomeprazole can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Esomeprazole can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Esomeprazole can be increased when combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Esomeprazole can be increased when it is combined with Fusidic Acid. Approved, Investigational Gefitinib The serum concentration of Gefitinib can be decreased when it is combined with Esomeprazole. Approved, Investigational Gemfibrozil The metabolism of Esomeprazole can be decreased when combined with Gemfibrozil. Approved Gliclazide The metabolism of Gliclazide can be decreased when combined with Esomeprazole. Approved Glucosamine The metabolism of Glucosamine can be decreased when combined with Esomeprazole. Approved, Investigational Glyburide The metabolism of Glyburide can be decreased when combined with Esomeprazole. Approved Guanfacine The metabolism of Guanfacine can be decreased when combined with Esomeprazole. Approved, Investigational Haloperidol The metabolism of Haloperidol can be decreased when combined with Esomeprazole. Approved Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Esomeprazole. Approved Ibandronate The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole. Approved, Investigational Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Esomeprazole. Approved Idelalisib The metabolism of Esomeprazole can be decreased when combined with Idelalisib. Approved Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Esomeprazole. Approved Imatinib The metabolism of Esomeprazole can be decreased when combined with Imatinib. Approved Imipramine The metabolism of Imipramine can be decreased when combined with Esomeprazole. Approved Indinavir The serum concentration of Indinavir can be decreased when it is combined with Esomeprazole. Approved Indomethacin The metabolism of Indomethacin can be decreased when combined with Esomeprazole. Approved, Investigational Iron Esomeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran Esomeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Iron saccharate Esomeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Isavuconazole The serum concentration of Esomeprazole can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Esomeprazole can be decreased when combined with Isavuconazonium. Approved, Investigational Isoniazid The metabolism of Esomeprazole can be decreased when combined with Isoniazid. Approved, Investigational Isradipine The metabolism of Esomeprazole can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The serum concentration of Itraconazole can be decreased when it is combined with Esomeprazole. Approved, Investigational Ivacaftor The serum concentration of Esomeprazole can be increased when it is combined with Ivacaftor. Approved Ixazomib The metabolism of Ixazomib can be decreased when combined with Esomeprazole. Approved, Investigational Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Esomeprazole. Approved, Investigational Ketoconazole The serum concentration of Ketoconazole can be decreased when it is combined with Esomeprazole. Approved, Investigational Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Esomeprazole. Approved, Investigational Lapatinib The metabolism of Lapatinib can be decreased when combined with Esomeprazole. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be decreased when it is combined with Esomeprazole. Approved Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Esomeprazole. Approved, Investigational Lobeglitazone The metabolism of Esomeprazole can be decreased when combined with Lobeglitazone. Approved, Investigational Lopinavir The metabolism of Esomeprazole can be decreased when combined with Lopinavir. Approved Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Esomeprazole. Approved Lorpiprazole The serum concentration of Esomeprazole can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Esomeprazole can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Esomeprazole can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Esomeprazole can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Esomeprazole. Approved, Investigational Macitentan The metabolism of Macitentan can be decreased when combined with Esomeprazole. Approved Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Esomeprazole. Experimental Melatonin The metabolism of Melatonin can be decreased when combined with Esomeprazole. Approved, Nutraceutical, Vet Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Esomeprazole. Investigational, Withdrawn Meprobamate The metabolism of Meprobamate can be decreased when combined with Esomeprazole. Approved, Illicit Mesalazine The therapeutic efficacy of Mesalazine can be decreased when used in combination with Esomeprazole. Approved Methadone The metabolism of Methadone can be decreased when combined with Esomeprazole. Approved Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Esomeprazole. Approved Methsuximide The metabolism of Methsuximide can be decreased when combined with Esomeprazole. Approved Methylphenidate Esomeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Investigational Methylphenobarbital The metabolism of Methylphenobarbital can be decreased when combined with Esomeprazole. Approved Metoprolol The metabolism of Metoprolol can be decreased when combined with Esomeprazole. Approved, Investigational Mifepristone The serum concentration of Esomeprazole can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Esomeprazole can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Moclobemide can be decreased when combined with Esomeprazole. Approved, Investigational Modafinil The metabolism of Esomeprazole can be decreased when combined with Modafinil. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole. Approved Nabiximols The metabolism of Nabiximols can be decreased when combined with Esomeprazole. Approved Nefazodone The metabolism of Esomeprazole can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy. Approved Netupitant The serum concentration of Esomeprazole can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Esomeprazole can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Esomeprazole can be decreased when combined with Nicardipine. Approved, Investigational Nicotine The metabolism of Nicotine can be decreased when combined with Esomeprazole. Approved Nilotinib The serum concentration of Nilotinib can be decreased when it is combined with Esomeprazole. Approved, Investigational Nilutamide The metabolism of Nilutamide can be decreased when combined with Esomeprazole. Approved, Investigational Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Esomeprazole. Approved Olaparib The metabolism of Esomeprazole can be decreased when combined with Olaparib. Approved Omeprazole The metabolism of Esomeprazole can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Osimertinib The serum concentration of Esomeprazole can be increased when it is combined with Osimertinib. Approved Ospemifene The metabolism of Ospemifene can be decreased when combined with Esomeprazole. Approved, Investigational Oxiconazole The metabolism of Oxiconazole can be decreased when combined with Esomeprazole. Approved Palbociclib The serum concentration of Esomeprazole can be increased when it is combined with Palbociclib. Approved, Investigational Pamidronate The therapeutic efficacy of Pamidronate can be decreased when used in combination with Esomeprazole. Approved Pantoprazole The metabolism of Esomeprazole can be decreased when combined with Pantoprazole. Approved Pazopanib The serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole. Approved Pentamidine The metabolism of Pentamidine can be decreased when combined with Esomeprazole. Approved, Investigational Pentobarbital The metabolism of Esomeprazole can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Esomeprazole. Approved Pethidine The metabolism of Pethidine can be decreased when combined with Esomeprazole. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Esomeprazole. Withdrawn Phenindione The serum concentration of Phenindione can be increased when it is combined with Esomeprazole. Approved, Investigational Phenobarbital The metabolism of Esomeprazole can be increased when combined with Phenobarbital. Approved, Investigational Phenprocoumon The serum concentration of Phenprocoumon can be increased when it is combined with Esomeprazole. Approved, Investigational Phenytoin The metabolism of Esomeprazole can be increased when combined with Phenytoin. Approved, Vet Approved Piperaquine The metabolism of Piperaquine can be decreased when combined with Esomeprazole. Approved, Investigational Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Esomeprazole. Approved, Investigational Pitolisant The serum concentration of Esomeprazole can be decreased when it is combined with Pitolisant. Approved, Investigational Podofilox The metabolism of Podofilox can be decreased when combined with Esomeprazole. Approved Posaconazole The serum concentration of Posaconazole can be decreased when it is combined with Esomeprazole. Approved, Investigational, Vet Approved Prasugrel The metabolism of Prasugrel can be decreased when combined with Esomeprazole. Approved Praziquantel The metabolism of Praziquantel can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Primidone The metabolism of Esomeprazole can be increased when combined with Primidone. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Esomeprazole. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Esomeprazole. Approved Promazine The metabolism of Promazine can be decreased when combined with Esomeprazole. Approved, Vet Approved Propofol The metabolism of Propofol can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Propranolol The metabolism of Propranolol can be decreased when combined with Esomeprazole. Approved, Investigational Quazepam The metabolism of Quazepam can be decreased when combined with Esomeprazole. Approved, Illicit Quetiapine The metabolism of Quetiapine can be decreased when combined with Esomeprazole. Approved Quinine The metabolism of Quinine can be decreased when combined with Esomeprazole. Approved Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Esomeprazole. Approved, Investigational Raltegravir The serum concentration of Raltegravir can be increased when it is combined with Esomeprazole. Approved Ramelteon The metabolism of Ramelteon can be decreased when combined with Esomeprazole. Approved, Investigational Ranitidine The metabolism of Ranitidine can be decreased when combined with Esomeprazole. Approved Ranolazine The metabolism of Esomeprazole can be decreased when combined with Ranolazine. Approved, Investigational Rifabutin The metabolism of Esomeprazole can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Esomeprazole can be decreased when it is combined with Rifampicin. Approved Rifapentine The metabolism of Esomeprazole can be increased when combined with Rifapentine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Esomeprazole. Approved Riociguat The serum concentration of Riociguat can be decreased when it is combined with Esomeprazole. Approved Risedronate The serum concentration of Risedronate can be increased when it is combined with Esomeprazole. Approved, Investigational Risedronate The therapeutic efficacy of Risedronate can be decreased when used in combination with Esomeprazole. Approved, Investigational Romidepsin The metabolism of Romidepsin can be decreased when combined with Esomeprazole. Approved, Investigational Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Esomeprazole. Approved Rucaparib The metabolism of Esomeprazole can be decreased when combined with Rucaparib. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Esomeprazole. Approved Saquinavir The serum concentration of Saquinavir can be increased when it is combined with Esomeprazole. Approved, Investigational Sarilumab The therapeutic efficacy of Esomeprazole can be decreased when used in combination with Sarilumab. Approved, Investigational Selegiline The metabolism of Selegiline can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Esomeprazole. Approved Sertraline The metabolism of Sertraline can be decreased when combined with Esomeprazole. Approved Sildenafil The metabolism of Esomeprazole can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Esomeprazole can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Esomeprazole can be increased when it is combined with Simeprevir. Approved St. John's Wort The serum concentration of Esomeprazole can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Esomeprazole can be increased when it is combined with Stiripentol. Approved Sulfisoxazole The metabolism of Esomeprazole can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Esomeprazole. Approved, Investigational Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Esomeprazole. Approved Tapentadol The metabolism of Tapentadol can be decreased when combined with Esomeprazole. Approved Technetium Tc-99m etidronate The therapeutic efficacy of Technetium Tc-99m etidronate can be decreased when used in combination with Esomeprazole. Approved Technetium Tc-99m medronate The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Esomeprazole. Approved Telaprevir The metabolism of Esomeprazole can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Esomeprazole can be decreased when combined with Telithromycin. Approved Temazepam The metabolism of Temazepam can be decreased when combined with Esomeprazole. Approved, Investigational Teniposide The metabolism of Teniposide can be decreased when combined with Esomeprazole. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Esomeprazole. Approved, Investigational, Vet Approved Testosterone The metabolism of Testosterone can be decreased when combined with Esomeprazole. Approved, Investigational Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Esomeprazole. Approved Testosterone enanthate The metabolism of Testosterone enanthate can be decreased when combined with Esomeprazole. Approved Testosterone undecanoate The metabolism of Testosterone undecanoate can be decreased when combined with Esomeprazole. Approved, Investigational Thalidomide The metabolism of Thalidomide can be decreased when combined with Esomeprazole. Approved, Investigational, Withdrawn Thioridazine The metabolism of Thioridazine can be decreased when combined with Esomeprazole. Approved, Withdrawn Ticlopidine The metabolism of Esomeprazole can be decreased when combined with Ticlopidine. Approved Tiludronic acid The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Esomeprazole. Approved, Investigational, Vet Approved Timolol The metabolism of Timolol can be decreased when combined with Esomeprazole. Approved Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with Esomeprazole. Experimental Tipranavir The serum concentration of Esomeprazole can be decreased when it is combined with Tipranavir. Approved, Investigational Tocilizumab The serum concentration of Esomeprazole can be decreased when it is combined with Tocilizumab. Approved Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Esomeprazole. Approved, Investigational Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Esomeprazole. Approved, Investigational Tolterodine The metabolism of Tolterodine can be decreased when combined with Esomeprazole. Approved, Investigational Topiramate The metabolism of Esomeprazole can be decreased when combined with Topiramate. Approved Trabectedin The metabolism of Trabectedin can be decreased when combined with Esomeprazole. Approved, Investigational Tranylcypromine The metabolism of Esomeprazole can be decreased when combined with Tranylcypromine. Approved, Investigational Trimethadione The metabolism of Trimethadione can be decreased when combined with Esomeprazole. Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Esomeprazole. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Esomeprazole. Investigational, Withdrawn Valproic Acid The metabolism of Valproic Acid can be decreased when combined with Esomeprazole. Approved, Investigational Vemurafenib The serum concentration of Esomeprazole can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Esomeprazole can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Esomeprazole can be decreased when combined with Verapamil. Approved Voriconazole The serum concentration of Esomeprazole can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Esomeprazole. Approved, Investigational Warfarin The serum concentration of Warfarin can be increased when it is combined with Esomeprazole. Approved Zidovudine The metabolism of Zidovudine can be decreased when combined with Esomeprazole. Approved Ziprasidone The metabolism of Esomeprazole can be decreased when combined with Ziprasidone. Approved Zoledronic acid The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Esomeprazole. Approved Zolpidem The metabolism of Zolpidem can be decreased when combined with Esomeprazole. Approved Zucapsaicin The metabolism of Esomeprazole can be decreased when combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Take without regard to meals.
References
- Synthesis Reference
Manne Reddy, "Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof." U.S. Patent US20040167173, issued August 26, 2004.
US20040167173- General References
- Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K: Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Jul;14(7):861-7. [PubMed:10886041]
- External Links
- Human Metabolome Database
- HMDB0005009
- KEGG Drug
- D07917
- PubChem Compound
- 9568614
- PubChem Substance
- 46504894
- ChemSpider
- 7843323
- ChEBI
- 50275
- ChEMBL
- CHEMBL1201320
- Therapeutic Targets Database
- DCL000524
- PharmGKB
- PA10075
- IUPHAR
- 4279
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Esomeprazole
- ATC Codes
- M01AE52 — Naproxen and esomeprazole
- M01AE — Propionic acid derivatives
- M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
- M — MUSCULO-SKELETAL SYSTEM
- A02BC — Proton pump inhibitors
- A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 56:28.36 — Proton-pump Inhibitors
- FDA label
- Download (104 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Astrazeneca lp
- Packagers
- AQ Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- AstraZeneca Inc.
- Cardinal Health
- Direct Pharmaceuticals Inc.
- Diversified Healthcare Services Inc.
- Innoviant Pharmacy Inc.
- Lake Erie Medical and Surgical Supply
- Merck & Co.
- Nucare Pharmaceuticals Inc.
- Palmetto Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Rebel Distributors Corp.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Dosage forms
Form Route Strength Capsule, delayed release Oral 20 mg/1 Capsule, delayed release Oral 20 1/1 Capsule, delayed release Oral 40 1/1 Capsule, delayed release Oral 40 mg/1 Capsule, delayed release pellets Oral 20 mg/1 Capsule, delayed release pellets Oral 40 mg/1 Injection, powder, lyophilized, for solution Intravenous 20 mg/1 Injection, powder, lyophilized, for solution Intravenous 20 mg/5mL Injection, powder, lyophilized, for solution Intravenous 40 mg/5mL Injection, powder, lyophilized, for solution Intravenous 40 mg/1 Capsule, delayed release Oral 24.65 mg/1 Capsule, delayed release Oral 49.3 mg/1 Granule, delayed release Oral 10 mg/1 Granule, delayed release Oral 10 mg Granule, delayed release Oral 2.5 mg/1 Granule, delayed release Oral 20 mg/1 Granule, delayed release Oral 40 mg/1 Granule, delayed release Oral 5 mg/1 Tablet, delayed release Oral 20 mg Tablet, delayed release Oral 40 mg Tablet Oral 20 mg/1 Injection Intravenous 20 mg/5mL Injection Intravenous 40 mg/5mL Kit Capsule, delayed release Oral 20 mg Capsule, delayed release Oral 40 mg Tablet, delayed release Oral - Prices
Unit description Cost Unit Nexium i.v. 20 mg vial 33.91USD vial Nexium i.v. 40 mg vial 33.91USD vial NexIUM 20 mg Delayed Release Capsule 6.76USD capsule NexIUM 40 mg Delayed Release Capsule 6.76USD capsule Nexium 10 mg packet 6.5USD each Nexium 20 mg capsule 6.5USD capsule Nexium 20 mg packet 6.5USD each Nexium 40 mg capsule 6.5USD capsule Nexium 40 mg packet 6.5USD each DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5877192 No 1994-05-27 2014-05-27 US CA1338377 No 1996-06-11 2013-06-11 Canada CA2346988 No 2009-02-10 2019-11-03 Canada US6191148 Yes 1999-04-09 2019-04-09 US US6147103 Yes 1999-04-09 2019-04-09 US US6166213 Yes 1999-04-09 2019-04-09 US US5900424 Yes 1996-11-04 2016-11-04 US US6369085 Yes 1998-11-25 2018-11-25 US US6428810 Yes 2000-05-03 2020-05-03 US US7411070 Yes 1998-11-25 2018-11-25 US US8466175 Yes 1998-11-25 2018-11-25 US US8852636 No 2002-05-31 2022-05-31 US US8858996 No 2002-05-31 2022-05-31 US US6926907 No 2003-02-28 2023-02-28 US US7745466 No 1998-10-13 2018-10-13 US US9161920 No 2002-05-31 2022-05-31 US US9198888 No 2002-05-31 2022-05-31 US US8945621 No 2011-10-17 2031-10-17 US US8557285 No 2002-05-31 2022-05-31 US US9220698 No 2011-03-10 2031-03-10 US US5714504 Yes 1995-08-03 2015-08-03 US US9345695 No 2002-05-31 2022-05-31 US US9393208 No 2009-09-03 2029-09-03 US US9707181 No 2002-05-31 2022-05-31 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 155 °C Not Available water solubility Very slightly soluble in water Not Available logP 0.6 Not Available - Predicted Properties
Property Value Source Water Solubility 0.353 mg/mL ALOGPS logP 1.66 ALOGPS logP 2.43 ChemAxon logS -3 ALOGPS pKa (Strongest Acidic) 9.68 ChemAxon pKa (Strongest Basic) 4.77 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 77.1 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 93.66 m3·mol-1 ChemAxon Polarizability 35.81 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9968 Blood Brain Barrier - 0.6326 Caco-2 permeable + 0.8867 P-glycoprotein substrate Non-substrate 0.5573 P-glycoprotein inhibitor I Inhibitor 0.6622 P-glycoprotein inhibitor II Non-inhibitor 0.968 Renal organic cation transporter Non-inhibitor 0.542 CYP450 2C9 substrate Non-substrate 0.7838 CYP450 2D6 substrate Substrate 0.6175 CYP450 3A4 substrate Substrate 0.6901 CYP450 1A2 substrate Inhibitor 0.7505 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8994 CYP450 3A4 inhibitor Inhibitor 0.796 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7895 Ames test Non AMES toxic 0.5692 Carcinogenicity Non-carcinogens 0.8318 Biodegradation Not ready biodegradable 0.9778 Rat acute toxicity 2.2254 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.719 hERG inhibition (predictor II) Non-inhibitor 0.8977
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzimidazoles
- Sub Class
- Sulfinylbenzimidazoles
- Direct Parent
- Sulfinylbenzimidazoles
- Alternative Parents
- Anisoles / Methylpyridines / Alkyl aryl ethers / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds show 2 more
- Substituents
- Sulfinylbenzimidazole / Anisole / Alkyl aryl ether / Methylpyridine / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide show 12 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole (CHEBI:50275)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sodium:potassium-exchanging atpase activity
- Specific Function
- Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
- Gene Name
- ATP4A
- Uniprot ID
- P20648
- Uniprot Name
- Potassium-transporting ATPase alpha chain 1
- Molecular Weight
- 114117.74 Da
References
- Saccar CL: The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009 Sep;5(9):1113-24. doi: 10.1517/17425250903124363. [PubMed:19606942]
- McKeage K, Blick SK, Croxtall JD, Lyseng-Williamson KA, Keating GM: Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs. 2008;68(11):1571-607. [PubMed:18627213]
- Vachhani R, Olds G, Velanovich V: Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):15-27. doi: 10.1586/17474124.3.1.15. [PubMed:19210109]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Klotz U: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006 Jul;44(7):297-302. [PubMed:16961157]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:17